Analytical Data
-
Gene name
LILRA4/ILT-7/CD85g
-
简介
The LILRA4/ILT-7/CD85g protein is a coreceptor that critically limits the innate immune response during viral infection through FCER1G signaling.It negatively regulates TLR7 and TLR9 signaling and reduces IFNA1, IFNA2, IFNA4, IFNB1, and TNF production in dendritic cells exposed to influenza virus or CpG dinucleotides.LILRA4/ILT-7/CD85g Protein, Human (HEK293, His) is the recombinant human-derived LILRA4/ILT-7/CD85g protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
Biological Activity
Measured by its binding ability in a functional ELISA. Immobilized Human LILRA4 at 1 μg/mL (100 μL/well) can bind biotinylated Human ANGPTL7. The ED50 for this effect is 58.08 ng/mL. Measured by its binding ability in a functional ELISA. Immobilized Human LILRA4 at 1 μg/mL (100 μL/well) can bind biotinylated Human ANGPTL7. The ED50 for this effect is 58.08 ng/mL.
-
Alternative Names
Leukocyte immunoglobulin-like receptor subfamily A member 4; Immunoglobulin-like transcript 7
-
Species
Human
-
Source
HEK293
-
Tag
C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P59901-1
-
Expression Region
E24-N446
-
AA Sequence
ENLLKPILWAEPGPVITWHNPVTIWCQGTLEAQGYRLDKEGNSMSRHILKTLESENKVKLSIPSMMWEHAGRYHCYYQSPAGWSEPSDPLELVVTAYSRPTLSALPSPVVTSGVNVTLRCASRLGLGRFTLIEEGDHRLSWTLNSHQHNHGKFQALFPMGPLTFSNRGTFRCYGYENNTPYVWSEPSDPLQLLVSGVSRKPSLLTLQGPVVTPGENLTLQCGSDVGYIRYTLYKEGADGLPQRPGRQPQAGLSQANFTLSPVSRSYGGQYRCYGAHNVSSEWSAPSDPLDILIAGQISDRPSLSVQPGPTVTSGEKVTLLCQSWDPMFTFLLTKEGAAHPPLRLRSMYGAHKYQAEFPMSPVTSAHAGTYRCYGSRSSNPYLLSHPSEPLELVVSGATETLNPAQKKSDSKTAPHLQDYTVEN
-
Protein Length
Extracellular Domain
-
Molecular Weight
60-75 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LILRA4, also known as ILT-7 or CD85g, is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which plays a crucial role in modulating immune responses. This receptor is predominantly expressed on plasmacytoid dendritic cells (pDCs) and is involved in the recognition of viral infections and the regulation of interferon production. Understanding the structure and function of LILRA4 is essential for elucidating its role in immune tolerance and potential implications in autoimmune diseases and cancer. Research on LILRA4 has revealed its ability to bind to major histocompatibility complex (MHC) class I molecules, influencing immune signaling pathways that can either promote or inhibit immune activation. The recombinant protein of LILRA4 is being studied for its therapeutic potential, including its application in enhancing antiviral responses and its role in tumor immunology. As the understanding of LILRA4's mechanisms deepens, it may pave the way for innovative treatments that harness its regulatory functions, contributing to advances in immunotherapy and the management of inflammatory conditions. The ongoing research aims to explore not only its biological roles but also the potential of LILRA4 as a target for novel drugs that could modulate immune responses in various clinical settings.











